Evaluation of the mechanisms how beta blockade therapy for sepsis can protect sepsis-induced organ injuries

Research Project

Project/Area Number	26462768
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Emergency medicine
Research Institution	Keio University
Principal Investigator	Takeshi Suzuki 慶應義塾大学, 医学部(信濃町), 講師 (80327600)
Project Period (FY)	2014-04-01 – 2017-03-31
Project Status	Completed (Fiscal Year 2016)
Budget Amount *help	¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000) Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000) Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000) Fiscal Year 2014: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
Keywords	敗血症 / β遮断薬 / Tリンパ球 / アポトーシス / 免疫能 / リンパ球 / 生存率 / 細胞死 / 臓器障害
Outline of Final Research Achievements	In this study, I evaluated the effect of beta blockade therapy on spleen T-lymphocytes in sepsis. After confirmation that catecholamine stimulation induced spleen T-lymphocytes apoptosis in a dose dependant manner, I evaluated the effect of beta blockade therapy on normal spleen T-lymphocytes, which were reduced according to the severity of sepsis. I used a cecum ligation and puncture (CLP) model as a septic model, which was a golden standard model for sepsis. Beta blockade therapy maintained the number of normal spleen T-lymphocytes, which were reduced dramatically in septic model. This result suggests that the preservation of immune function through manintenance of T-lymphocytes may be one of beneficial effects of beta blockde therapy in sepsis.